Loading financial data...

bioAffinity Technologies, Inc.

BIAFWSEC EDGAR

Services-Commercial Physical & Biological Research(DE)CIK: 1712762

Concept	FY2024	FY2023	FY2022
Revenue from Contract with Customer, Excluding Assessed Tax	$2.5M	$4.8K	$4.8K
Cost of Revenue	—	—	$467.00
Gross Profit	—	—	$4.3K
Research and Development Expense	$1.5M	$1.4M	$1.0M
Selling, General and Administrative Expense	$6.8M	$2.5M	$1.1M
Operating Expenses	$10.5M	$4.0M	$2.2M
Operating Income (Loss)	-$8.0M	-$4.0M	-$2.2M
Interest Expense	—	$2.5M	$1.0M
Nonoperating Income (Expense)	$57.2K	-$4.1M	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$7.9M	-$8.2M	-$6.3M
Income Tax Expense (Benefit)

Concept	FY2024	FY2023	FY2022
Assets	$8.2M	$12.2M	$1.5M
Assets, Current	$4.0M	$12.0M	$1.4M
Cash and Cash Equivalents, at Carrying Value	$2.8M	$11.4M	$1.4M
Inventory, Net	$18.5K	$5.5K	$5.5K
Liabilities	$3.4M	$1.1M	$13.2M
Liabilities, Current	$2.2M	$1.1M	$13.0M
Accounts Payable, Current	$604.8K	$345.0K	$230.4K
Stockholders' Equity Attributable to Parent	$11.0M	-$15.8M	-$15.1M
Common Stock, Shares, Outstanding	$9.4M	$8.4M	$2.7M

Concept	FY2024	FY2023	FY2022
Net Cash Provided by (Used in) Operating Activities	-$6.0M	-$4.1M	-$2.0M
Net Cash Provided by (Used in) Investing Activities	-$2.2M	-$220.0K	-$220.0K
Net Cash Provided by (Used in) Financing Activities	-$345.0K	$14.3M	$3.3M
Payments to Acquire Property, Plant, and Equipment	$22.9K	$220.0K	$220.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)

bioAffinity Technologies, Inc. (BIAFW) Financial Statements | Global Financial Data